About Antares Medicines For Partners For Investors For PatientsCareers Contact Us Executive Leadership Robert F. Apple, President and Chief Executive Officer Mr. Apple has over 25 years of senior leadership experience in the pharmaceutical industry focusing on operations, strategy, sales and finance. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. In September 2014, Mr. Apple was promoted to the position of Executive Vice President, Chief Operating Officer of the Company. Mr. Apple was promoted to President and Chief Executive Officer in January 2016 and was appointed to the Board of Directors in March 2016. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. from 2003 to 2005, and Chief Financial Officer from 1997 to 2002. From 1995 to 1997, Mr. Apple was employed by Genaera Corporation, Inc., a biotechnology company, where he held the position of Corporate Controller. From May 1994 until July 1995, Mr. Apple was employed by Liberty Technologies, Inc. as Corporate Controller. Prior to May 1994, Mr. Apple held various positions of increasing responsibility at Arthur Andersen & Company LLP. He holds a B.A. degree in accounting from Temple University. Fred Powell, Executive Vice President and Chief Financial Officer Mr. Powell joined the Company in November of 2016 as Senior Vice President and Chief Financial Officer. Prior to joining Antares, from 2012 until 2016 Mr. Powell served as Vice President and Chief Financial Officer for Celator Pharmaceuticals, which was a publicly traded biopharmaceutical company engaged in the development of a portfolio of cancer therapies. At Celator, he was responsible for the Company’s accounting, corporate finance and financial planning functions. From 2011 until 2012, Mr. Powell was the chief financial officer of OraPharma, Inc. where he helped develop and grow the specialty healthcare company. Mr. Powell was chief financial officer of BMP Sunstone Corporation, a publicly traded U.S. specialty pharmaceutical company from 2005 until 2011. Mr. Powell also held senior finance and administration positions at Eximias Pharmaceutical Corporation, Innaphase Corporation and ERT. Mr. Powell began his career with KPMG Peat Marwick and holds a B.S. in Accounting from of Pennsylvania State University. Peter J. Graham ESQ., Executive Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary Mr. Graham joined the Company in July 2015 as Senior Vice President, General Counsel, Chief Compliance Officer, Human Resources and Corporate Secretary and has more than 20 years of legal and executive management experience in publicly and privately held pharmaceutical and medical device companies. From 2010 until 2015, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources for Delcath Systems, Inc. (NASDAQ: DCTH), a late-stage clinical development company focused on cancers of the liver. From 2008 until 2010, Mr. Graham was Vice President, General Counsel and a member of the Executive Committee of ACIST Medical Systems, Inc., a subsidiary of Bracco, SpA., a global company specializing in cardiovascular and diagnostic imaging solutions. Prior to ACIST, Mr. Graham spent 11 years at E-Z- EM, Inc. (NASDAQ: EZEM), a global medical device and pharmaceutical company specializing in CT and MR imaging solutions where he served as Senior Vice President, Chief Legal Officer, and Global Human Resources and Secretary. From 1997 until 2004, Mr. Graham also served as General Counsel and Corporate Secretary for AngioDynamics, Inc. (NASDAQ: ANGO), then a wholly owned subsidiary of EZEM, a leading provider of interventional medical devices. Mr. Graham earned his J.D. at Yeshiva University's Benjamin N. Cardozo School of Law in 1995, and his B.A. in Political Science at the University of Wisconsin-Madison. Dr. Peter Richardson, Executive Vice President, Research and Development and Chief Medical Officer Dr. Richardson joined the company in April 2021 as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Richardson has over 25 years of research and development experience in the pharmaceutical and medical device industry. He has created centers of excellence that have enabled and supported product development pipelines encompassing small molecules, biologics, novel formulations, combination products, and medical devices. During his career, Dr. Richardson has managed clinical development programs leading to the submission, review, and approvals of NDAs, sNDAs, BLAs and Marketing Authorization Applications in the U.S., Europe and Japan for over 20 marketed products. Prior to joining Antares, Dr. Richardson was Chief Medical Officer for Adare Pharmaceuticals and Vice President of Research and Development and President, Adare Pharmaceuticals US from 2016 until the acquisition of the company in 2020. From 2012 to 2016, he served as Head of Clinical and Regulatory Affairs and Chief Medical Officer at Alcon, the eye care division of Novartis, having previously led development organizations for Novartis Pharmaceuticals from 1996 to 2005, where he was responsible for successful product approvals in multiple therapeutic areas. He also previously served as Chief Scientific Officer and Corporate Vice President of MannKind Corporation from 2005 to 2012. Dr. Richardson earned his Bachelor of Medical Sciences from the University of Nottingham and his Bachelor of Medicine and Bachelor of Surgery from the University of Nottingham Medical School. He is a member of the Royal College of Physicians, United Kingdom. Greg DeFilippis, Senior Vice President, Device Business and Alliances Mr. DeFilippis joined the Company in July 2013 as Senior Director, Business Alliances and Device Supply Chain Management and was promoted to the position of Vice President, Business Development and Alliances in December 2014. In December 2019, Mr. DeFilippis was promoted to Senior Vice President, Device Business and Alliances. Prior to joining the Company Mr. DeFilippis served as Director of Business Development for Teva Pharmaceuticals. Prior to joining Teva, Mr. DeFilippis held increasing roles of responsibility in technical operations, supply chain and continuous improvement at Barr Laboratories, Inc., Pliva, Inc., Actavis, Inc. and Alpharma. Mr. DeFilippis holds a B.S. in Industrial and Systems Engineering from Virginia Tech, a M.B.A. in Finance from Fairleigh Dickinson University and is a Certified Lean Six Sigma Master Black Belt. Joseph Renda, Senior Vice President of Commercial Mr. Renda joined Antares as Senior Vice President of Commercial in May 2021. Joe has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various positions of increasing responsibility at Novo Nordisk including Marketing Brand Director, Women’s Health Care and leading the commercial operations and effectiveness function responsible for a 150-person sales force. He was ultimately promoted to Vice President, U.S. Sales Biopharmaceutical Division leading a national sales team with over $600M in annual sales. Prior to that, he was Regional Business Director at Pfizer managing one of the largest U.S. sales regions with 175 sales and account representatives after serving in varying director and operational roles. He also previously served as Manager, U.S. Urology Marketing and Alliances at the Pharmacia Corporation and began his career in sales at The Upjohn Company. Mr. Renda earned his Bachelor of Science degree from Pennsylvania State University. Dr. Steven Knapp, Senior Vice President, Regulatory Affairs and Quality Assurance Dr. Knapp is a seasoned regulatory and quality executive with over 30 years of experience in the pharmaceutical and device industry and a proven track record of building and managing regulatory and quality departments in both large and small organizations. Most recently, Dr. Knapp served as Vice President, Global Regulatory Affairs and Scientific Communications at Endo Pharmaceuticals. Prior to Endo, he was Global Vice President of Regulatory and Quality at Valeant Pharmaceuticals and served in a similar position at Ikaria. Earlier in his career, Steven spent 13 years at Bristol Myers Squibb (BMS) holding various positions of increasing responsibility in the regulatory affairs and quality assurance departments. Prior to BMS, Steve worked at Schering-Plough, in the area of International Regulatory Affairs, as well as J&J Research and Ortho Pharmaceuticals in the areas of pharmaceutical development and manufacturing. Dr. Knapp earned his Bachelor of Science in Pharmacy, Master of Science in Manufacturing/Packaging Engineering and Doctorate of Pharmacy from Rutgers University in New Brunswick, NJ. Patrick Madsen, Senior Vice President, Operations Mr. Madsen joined the Company in November 2010 as Vice President of Product Development, Parenteral Products Division. Prior to joining the Company, Mr. Madsen was employed at Hutchinson Technology Inc., from 1999 to 2010, in positions of increasing responsibility, most recently serving as Director of Engineering in the BioMedical Division. Mr. Madsen successfully led the development and commercial launch of Hutchinson’s advanced mobile sensors for monitoring tissue oxygenation. Prior to joining Hutchinson Technology, Mr. Madsen was employed by Boston Scientific Corporation, Inc. He holds a B.S. in Mechanical Engineering degree from the University of North Dakota. Peter Sadowski, Ph.D., Senior Vice President, Technology Portfolio and Intellectual Property Dr. Sadowski joined Medi-Ject Corporation, a predecessor company to Antares Pharma, in March 1994 as Vice President, Product Development. In 2001 Dr. Sadowski became Vice President of the Company’s Devices Group where he led the conceptualization and development of the VIBEX mini-needle injection technology platform. In 2009 he was promoted to Senior Vice President and General Manager, Parenteral Products Group. Prior to joining the Company, Dr. Sadowski led product development teams at Molecular Genetics, Inc., GalaGen, Inc., and American Biosystems, Inc. Dr. Sadowski holds a Ph.D. in microbiology from the University of Minnesota. Ed Tykot, Senior Vice President, Corporate Business Development Mr. Tykot joined Antares in December of 2019 as the Senior Vice President of Corporate Business Development. He brings 30 years of pharmaceutical experience to the company. Prior to joining Antares, Mr. Tykot held increasing roles of responsibility in marketing and business development at Watson Pharmaceuticals, Inc., Actavis, Inc., Eagle Pharmaceuticals, Inc., and Nevakar, Inc. Mr. Tykot holds a B.S. in Biology from Tufts University and an M.B.A. in Marketing and Management from New York University Stern School of Business. About Antares About Us Management Board of Directors Compliance This site ©2021 Antares Pharma. All Rights Reserved About Antares Medicines For Partners For Investors For Patients Careers Contact Us Privacy Policy